$695 | Single User
$1395 | Global License

Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Jun 2015 | 235 | In Stock
Related Topics: FDA , Roche



The data presented at this year's ASCO annual meeting, which has subsequently fuelled the most debate, is likely that from Bristol-Myers Squibb's Checkmate-057 study, assessing its PD-1 inhibitor Opdivo for the treatment of second-line non-squamous non-small-cell lung cancer (NSCLC).

Results from the Checkmate-057 study illustrated that Opdivo was associated with a 27-percent reduction in the risk of progression or death compared to docetaxel, positioning Bristol-Myers Squibb's product as the first PD-1 inhibitor to show a significant improvement in overall survival in a Phase III trial in non-squamous NSCLC compared with the current standard of care.

A subsequent analysis of survival based on PD-L1 expression demonstrated that this benefit was driven, however, by those patients who had pre-specified PD-L1 expression levels of 10 percent or more. Investors sent Bristol-Myers Squibb's share price down as a result, given a consensus-supported view that Opdivo was likely to work in all non-squamous NSCLC patients, irrespective of PD-L1 status (FirstWord Lists: Best selling cancer drugs - 2014 and 2020).

An earlier study – Checkmate-017, used to support approval of Opdivo in second-line squamous NSCLC – had supported this view and appeared to validate Bristol-Myers Squibb's status as a "reluctant adopter of PD-L1 testing" in the advanced lung cancer indication, noted Bernstein analyst Tim Anderson. The consequences of these 'unexpected' data from Checkmate-057 are a potential opportunity for rival players Roche and Merck & Co. to be more competitive in second-line lung cancer and the strength of Bristol-Myers Squibb's biomarker capabilities (ViewPoints: Opdivo disappoints in lung cancer – Bristol-Myers Squibb’s pain could be Merck & Co., Roche’s gain).

Clinical and regulatory implications stemming from the PD-L1 as a biomarker debate will increasingly converge in the coming months, based on submission of Opdivo for approval in non-squamous NSCLC based on the Checkmate-057 data, confirmation that Merck's Keytruda has been accepted for priority review (based on data in PD-L1 positive patients, but with management taking up the potential for a broad label) and with Roche expected to file its PD-L1 inhibitor in advanced lung cancer in late 2015/early 2016.

With these factors in mind, Anderson wrote in a note to investors this week "it seems to us that this matter will be headed to an FDA advisory committee at some point soon. The agency would want to discuss the role of PD-L1 testing both in product labels and in clinical practice, within the limits of the clinical trial data it currently has. Clearly, the biomarker situation is fluid, but increasingly there seems to be concordance among different companies' findings."

Puchase Reasons

On the back of the Checkmate-057 data presented at ASCO, and fuelled by increasing debate around the validity of PD-L1 as a biomarker in the sizeable market for advanced NSCLC, we are polling US and EU5 oncologists this week with the following questions…

  • Based on data from the Checkmate-057 study presented at ASCO (http://news.bms.com/press-release/opdivo-nivolumab-first-pd-1-inhibitor-demonstrate-superior-overall-survival-versus-sta), do you think Opdivo should be approved with a broad label for the treatment of all second-line non-squamous NSCLC patients – i.e. PD-L1 expressers and non-expressers?

  • Assuming a broad label is approved, how would you expect to use Opdivo in PD-L1 non-expressing patients?

  • If competing PD-1/PD-L1 inhibitors reach the market for the treatment of second-line NSCLC with labelling restricted to PD-L1 expressers (given selection by biomarker for pivotal stage study enrolment), would you likely use these products in non-expressing patients also?

  • Do you think that approval of subsequent therapies labelled specifically for PD-L1 expressing, second-line NSCLC patients – and launched with companion diagnostics – would support more proactive patient stratification on your part and the use of these treatments more frequently in PD-L1 expressing patients (i.e. do you expect more stratification of this indication over time)?

  • Based on you reading of current data, how confident are you in the use of PD-L1 as an effective biomarker in lung cancer? Confused with current discussion around PD-L1
  • Table of Contents
    for Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer

    Additional Details


    FirstWord Pharma

    Publisher Information


    235 |

    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...